Ms. Page is a diagnostics industry veteran with over 25 years executive experience, including commercialization, business development and general management of leading companies who are among Sword’s target customers.
In January 2013 Ms. Page founded Vineyard Investment Advisors. VIA is focused on partnering with entrepreneurs, businesses, and universities to transform their ideas into products and services. Prior to this venture, Ms. Page served as the President / CEO of Vermillion, Inc. from Jan 2006 thru December 2012. She was a member of the board from 2006 thru 2012 and served as Chairperson from 2010-2011. Vermillion is a healthcare company focused on developing and commercializing novel diagnostic blood test. Upon joining Vermillion in 2004 she inspired a pioneering spirit. Under her leadership the company was repositioned to embrace the progressive nature of its pipeline, successfully raised over $100M in funding, developed and commercially launched the first FDA-cleared blood test to help diagnose ovarian cancer. Ms. Page has spent her entire career in health care and has a passion for emerging technologies that advance the efforts in personalized medicine.
CEO and Founder, Sword Bio
Mr. Dingott is a Fortune-10 trained business leader with 30 years’ experience identifying, creating and leading businesses from proof of concept to successful commercial enterprise.
To help navigate Sword toward success, Mr. Dingott has cultivated relationships with an elite network of industry leaders with strategic insight and extensive corporate relationship connections. In addition, Mr. Dingott serves on the board of directors of Cearna, Inc, which sells a unique gel based patch that dramatically reduces pain, swelling and bruising that is the result of trauma or surgical procedures.
Mr. Schatz has 30 years of leadership experience in healthcare and senior management postions in diagnostics and devices with companies including Marion Laboratories, Medtronic, Bacchus Labs and Abbott Labs.
Mr. Schatz’s experience with Abbott Labs included worldwide management of the Cancer Business Unit headquartered in the U.S. and Director of Marketing for Dainabot, Abbott joint venture in Japan. After fulfilling both of these roles subsequently, Mr. Schatz was promoted to Vice President of Abbott Diagnostics, Asia Pacific and President of Dainabot (combined diagnostic/pharmaceutical entity in Japan). Mr. Schatz also held positions as Vice President and Sector Manager, for Abbott’s benchtop analyzers and physician office diagnostics.
This experience has provided Mr. Schatz with a wide variety of skills including extensive international experience and Expertise with healthcare specialists and investors to define business opportunities.
V. Edward Grogg is the President/CEO and Founder of Carmel, Indiana based Ellipsis Ventures, LLC. Ellipsis Ventures is an investment company specializing in senior care real estate and health care technology companies that are laser focused on differentiating themselves within their respective markets. Ellipsis partners with companies to assist them in bringing the necessary capital for the expansion of their products as well as to assist them in achieving their overall growth plans.
Prior to Ellipsis, Mr. Grogg was the President/Principal of Carmel, Indiana based Mainstreet Property Group, the largest developer of Next Generation™ Skilled Nursing & Short Term Rehabilitation properties in North America. With 35+ years of experience in the senior living field, Mr. Grogg’s background in leadership and management oversight allowed him to be actively involved in all aspects of the company’s growth including acquisitions, new development and operator relationships. During his tenure at Mainstreet, the company grew from ~$25,000,000 in assets to ~$1,000,000,000 in assets over the 7 year period. Also during this period, the company launched a successful IPO on the Toronto Stock Exchange under HealthLease Properties REIT on June 20, 2012. HealthLease was later sold to Health Care REIT (HCN) in November 2014. Mr. Grogg joined Mainstreet in May 2007 as a partner and sold his interests in June 2014.